Latest Breaking News On - Johannes oldenburg - Page 1 : comparemela.com

Training the Immune System To Be Tolerant Could Help Hemophilia Sufferers

Hemophilia A is the most common severe form of hemophilia and can be treated well, but not for all sufferers. But scientist have now elucidated an important immune mechanism that could help tailor treatment to patients.

Nordrhein westfalenJohannes oldenburgJanine becker gototChristian kurtsUniversity of bonnInstitute for experimental haematologyInstitute of molecular medicineTransdisciplinary research area life healthUniversity hospital bonnClinical investigationExperimental haematologyTransfusion medicineMolecular medicineExperimental immunologyTransdisciplinary research area

Study elucidates mechanism that is crucial for making hemophilia therapy effective

Hemophilia A is the most common severe form of hemophilia. It affects almost exclusively males. The disease can usually be treated well, but not for all sufferers.

Nordrhein westfalenJohannes oldenburgJanine becker gototChristian kurtsEmily hendersonUniversity of applied sciences in krems austriaInstitute for experimental haematologyUniversity hospital bonn bonforInstitute of molecular medicineUniversity hospital bonnGerman research foundationUniversity of bonnEuropean innovative medicines initiativeUniversity of melbourneTransdisciplinary research area life healthInstitute of experimental haematology

Training immune system to be tolerant

Training immune system to be tolerant
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Nordrhein westfalenAndreas pannekThilo albertChristian kurtsMirjam meissnerBlanca jurado mestrePaula gleesonJohannes oldenburgBirgitm reipertJanine becker gototAndrea maioneFranka schildbergVadim kotovUniversity of applied sciences in krems austriaInstitute for experimental haematologyUniversity hospital bonn bonfor

Europe approves first gene therapy for treatment of haemophilia A

Europe approves first gene therapy for treatment of haemophilia A
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

United statesNordrhein westfalenJohannes oldenburgJean jacques bienaimUniversity clinic in bonnEuropean commissionDrug administrationHaemophilia centreEuropean unionEuropean medicines agencyInstitute of experimental haematologyProfessor johannes oldenburgExperimental haematologyTransfusion medicineUniversity clinicMiddle east

First Gene Therapy for Adults with Severe Hemophilia A, BioMarin s ROCTAVIAN™ (valoctocogene roxaparvovec), Approved by European Commission (EC)

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the European Commission (EC) has granted conditional marketing authorization (CMA) to ROCTAVIAN™ (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients without a .

Nordrhein westfalenUnited statesJohannes oldenburgJean jacques bienaimUniversity clinic in bonnEuropean commissionBiomarin pharmaceutical incHaemophilia centreReplay international numberExchange commissionInternational numberPrnewswire biomarin pharmaceutical incEuropean medicines agencyRobust clinical programInstitute of experimental haematologyMaintains orphan drug designation